<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-12-03" updated="2020-01-02">
  <drugbank-id primary="true">DB11254</drugbank-id>
  <name>Hexylresorcinol</name>
  <description>Hexylresorcinol is a substituted dihydroxybenzene. It exhibits antiseptic, anthelmintic, and local anesthetic properties. It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain relief and first aid antiseptic.&#13;
&#13;
The compound may also be used commonly in various commercial cosmetic anti-aging creams while ongoing studies research the possibility of using hexylresorcinol as an anti-cancer therapy - indications all of which require further study and testing at the current moment.</description>
  <cas-number>136-77-6</cas-number>
  <unii>R9QTB5E82N</unii>
  <average-mass>194.2701</average-mass>
  <monoisotopic-mass>194.13067982</monoisotopic-mass>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A27155</ref-id>
        <pubmed-id>22579007</pubmed-id>
        <citation>McNally D, Shephard A, Field E: Randomised, double-blind, placebo-controlled study of a single dose of an amylmetacresol/2,4-dichlorobenzyl alcohol plus lidocaine lozenge or a hexylresorcinol lozenge for the treatment of acute sore throat due to upper respiratory tract infection. J Pharm Pharm Sci. 2012;15(2):281-94.</citation>
      </article>
      <article>
        <ref-id>A33017</ref-id>
        <pubmed-id>28930240</pubmed-id>
        <citation>Mace S, Truelstrup Hansen L, Rupasinghe HPV: Anti-Bacterial Activity of Phenolic Compounds against Streptococcus pyogenes. Medicines (Basel). 2017 May 1;4(2). pii: medicines4020025. doi: 10.3390/medicines4020025.</citation>
      </article>
      <article>
        <ref-id>A33020</ref-id>
        <pubmed-id>29011050</pubmed-id>
        <citation>Maplestone PA, Mukerji AK: Hexylresorcinol as an Anthelmintic. Ind Med Gaz. 1932 Nov;67(11):610-612.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2734</ref-id>
        <title>DailyMed: S.T.37-hexylresorcinol solution monograph</title>
        <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d7acca2-aa8a-5272-e813-faab039cc798</url>
      </link>
      <link>
        <ref-id>L2735</ref-id>
        <title>Electronic Medicines Compendium: Strepsils (hexylresorcinol) Extra Triple Action Blackcurrant Lozenges Monograph</title>
        <url>https://www.medicines.org.uk/emc/product/5601/smpc</url>
      </link>
      <link>
        <ref-id>L2736</ref-id>
        <title>Hexylresorcinol: Providing Skin Benefits by Modulating Multiple Molecular Targets</title>
        <url>https://www.researchgate.net/publication/283776287_Hexylresorcinol_Providing_Skin_Benefits_by_Modulating_Multiple_Molecular_Targets</url>
      </link>
      <link>
        <ref-id>L2739</ref-id>
        <title>NIH Toxnet: Hexylresorcinol Profile</title>
        <url>https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+566</url>
      </link>
      <link>
        <ref-id>L2740</ref-id>
        <title>IPCS INCHEM 4-Hexylresorcinol Profile</title>
        <url>http://www.inchem.org/documents/jecfa/jecmono/v35je04.htm</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F57</ref-id>
        <title>Health Products Regulatory Authority of Ireland: Summary of Product Characteristics for Hexylresorcinol</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/057/original/LicenseSPC_PA0979-042-001_08122016162037.pdf?1525986082</url>
      </attachment>
      <attachment>
        <ref-id>F58</ref-id>
        <title>University of Utah College of Pharmacy: Topical Analgesic and Anaesthetic Agents Drug Class Review</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/058/original/Topical_Analgesics_and_Anesthetics_Drug_Class_Review.pdf?1525986844</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>Hexylresorcinol is predominantly employed as the active ingredient in lotions, sprays, or lozenges indicated as a (a) topical antiseptic to help prevent skin infection in minor cuts, scrapes, or burns, or (b) as an antiseptic and local anesthetic for the relief of a sore throat and its associated pain [L2734, L2735].&#13;
&#13;
In addition, hexylresorcinol is used as an active ingredient in various commercial cosmetic skincare products as an anti-aging cream [L2736] while other studies have looked into whether or not the compound could be used effectively as an anti-inflammatory agent or even as an anti-cancer therapy [L2736].</indication>
  <pharmacodynamics>Hexylresorcinol is a phenol derivative, and in typical therapeutic usage is primarily a local anesthetic for topical use on the mucous membranes of the mouth and throat [F57]. The local anesthetic like properties of hexylresorcinol is likely due to its sodium channel blocking effects [F57]. The agent also demonstrates mild antiseptic activity as well as an apparent anti-inflammatory, demulcent action [F57].</pharmacodynamics>
  <mechanism-of-action>When acting as an oral anesthetic for relieving sore throats, it is generally believed that hexylresorcinol is possibly capable of blocking voltage-gated neuronal sodium channels, which in turn would inhibit the initiation and conduction of nerve impulses for feeling or transmitting pain signals in the local area to which the hexylresorcinol is applied [F58].&#13;
&#13;
As an antiseptic agent, studies have demonstrated that hexylresorcinol is capable of eliciting actions like reducing or inhibiting the generation of bacterial biofilm, interfering with bacterial cell chain formation, reducing bacterial adherence of the pharynx, inhibition of glycolytic enzyme and pH drops, and alteration of cell surface hydrophobicity [A33017]. Unfortunately, there are either antibiotics that function even more effectively at formally treating bacterial growth or there are also other plant-derived phenolic compounds similar to hexylresorcinol that elicit stronger such mechanisms of action [A33017]. Nevertheless, it is useful for hexylresorcinol to have both anesthetic and certain antiseptic actions for its use in treating various relatively self-limiting scrapes and sore throats that are treated by the over-the-counter products that feature the compound. Early studies in the 1930s and 1940s suggested that there were more effective medicines over hexylresorcinol that could be employed for their anthelmintic effects [A33020].&#13;
&#13;
As an anti-inflammatory and anti-aging agent, some studies have shown that it may be possible for hexylresorcinol to inhibit the phosphorylation of the immune response mediator NF-kappaB and also elicit a significant skin lightening effect owing to a strong inhibitory effect on tyrosinase and peroxidase and a stimulatory effect on glutathione and E-cadherin syntheses [L2736]. It is proposed that hexylresorcinol can bind to tyrosinase directly and inhibits its enzyme activity [L2736]. Literature data suggests that low glutathione levels relates to the deposition of melanin in the skin of humans and other animals, while high glutathione levels inhibit melanogenesis [L2736]. And ultimately, it is also reported that glutathione depletion increases tyrosinase activity in human melanoma cells, which makes hexylresorcinol's effects on tyrosinase desirable [L2736].&#13;
&#13;
Finally, there are ongoing studies that have reported hexylresorcinol's abilities to induce the differentiation of SCC-9 squamous cell cell-line by way of the modulation of the E2F-mediated signaling pathway and suppress the growth of squamous cell carcinoma SCC-9 cells in a dose-dependent manner [L2736]. Moreover, such studies have also shown that hexylresorcinol is seemingly capable of dose-dependent induction of SCC-9 cell apoptosis as well as the inhibition of transglutaminase-2 enzyme activity which can facilitate chemotherapy resistance [L2736].</mechanism-of-action>
  <toxicity>In the over-the-counter antiseptic and oral analgesic sprays and lozenges that hexylresorcinol is typically employed as the active ingredient, it is noted that overdosage of the agent may cause minor gastrointestinal irritation [L2735, F57, F58]. &#13;
&#13;
The probable oral LD50 of hexylresorcinol in humans has been estimated to be between 500 and 5000 mg/kg body weight, between 1 oz and 1 pint (or 1 lbs) for a 70 kg person [L2739, L2740].</toxicity>
  <metabolism>Regarding the metabolism of hexylresorcinol, it has been reported that excretion of the compound in the urine is largely in the form of an ethereal sulfate conjugate [L2739].</metabolism>
  <absorption>Owing to the poor absorption of hexylresorcinol, systemic exposure and symptoms are unusual [L2739].</absorption>
  <half-life>Readily accessible data regarding the half-life of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].</half-life>
  <protein-binding>Readily accessible data regarding the protein binding of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].</protein-binding>
  <route-of-elimination>When two men received doses of 1 g of hexylresorcinol, an average of 18% of the dose was recovered in the urine within the first 12 hours - thereafter, the compound was not detected in urine samples [L2739].</route-of-elimination>
  <volume-of-distribution>Readily accessible data regarding the volume of distribution of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].</volume-of-distribution>
  <clearance>Readily accessible data regarding the clearance of hexylresorcinol is not available. Nevertheless, when hexylresorcinol is employed in its primary indication as a topical antiseptic or an oral anesthetic, it is generally accepted that pharmacokinetic considerations do not arise since the pharmacological action is local to the topically applied or oro-pharyngeal cavity area [L2735, F57, F58].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as resorcinols. These are compounds containing a resorcinol moiety, which is a benzene ring bearing two hydroxyl groups at positions 1 and 3.</description>
    <direct-parent>Resorcinols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Phenols</class>
    <subclass>Benzenediols</subclass>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>1-hydroxy-4-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Benzene and substituted derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>1-hydroxy-4-unsubstituted benzenoid</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Resorcinol</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">4-hexyl-1,3-benzenediol</synonym>
    <synonym language="english" coder="">4-hexylresorcinol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Antiseptic Sore Throat Loz. (lemon Flavour)</name>
      <labeller>H.J. Sutton Industries Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02227568</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-24</started-marketing-on>
      <ended-marketing-on>1999-03-23</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antiseptic Sore Throat Loz(honey Eucalyp.fl)</name>
      <labeller>H.J. Sutton Industries Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02227541</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-03</started-marketing-on>
      <ended-marketing-on>1999-03-23</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antiseptic Sore Throat Loz(mint Menthol Flv)</name>
      <labeller>H.J. Sutton Industries Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02228424</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-03</started-marketing-on>
      <ended-marketing-on>1999-03-23</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Antiseptic Throat Lozenges (with Hexylresorcinol)</name>
      <labeller>H.J. Sutton Industries Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02228432</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-01-03</started-marketing-on>
      <ended-marketing-on>2013-07-05</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Avapta</name>
      <labeller>Neel Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76332-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-16</started-marketing-on>
      <ended-marketing-on>2015-10-13</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Avapta</name>
      <labeller>Neel Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76332-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-16</started-marketing-on>
      <ended-marketing-on>2015-10-13</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Avapta</name>
      <labeller>Neel Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>76332-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-08-06</started-marketing-on>
      <ended-marketing-on>2015-10-13</ended-marketing-on>
      <dosage-form>Spray</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Bradosol Lozenges Extra Strength 3.5mg</name>
      <labeller>Columbia Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00895466</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bradosol Lozenges Extra Strength 3.5mg Mint</name>
      <labeller>Columbia Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00894214</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bradosol Lozenges Regular Strength 2.4mg (cherry, Mint, Lemon, Orange, Honey-eucalyptus)</name>
      <labeller>Columbia Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00846589</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bradosol Multiflavour Loz 2.4mg</name>
      <labeller>Ciba Self Medication</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01919148</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bronchodex Past.antisep.-s.miel Et Eucalypt.</name>
      <labeller>Prodemdis Enr.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02033771</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2010-07-15</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bronchodex Past.antisept. Extra Fortes-S.cer</name>
      <labeller>Prodemdis Enr.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02031809</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2010-07-15</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bronchodex Pastilles Antiseptiques-S.cerise</name>
      <labeller>Prodemdis Enr.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02033127</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2010-07-19</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Bronchodex Pastilles Antiseptiques-S.menthe</name>
      <labeller>Prodemdis Enr.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02033690</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2010-07-15</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cherry Antiseptic Throat Lozenges 2.4mg/loz</name>
      <labeller>Ksl Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01996797</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Green Guard Sore Throat Relief</name>
      <labeller>Unifirst First Aid</labeller>
      <ndc-id/>
      <ndc-product-code>47682-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on>2015-01-26</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Honey Eucalyptus Antiseptic Throat Loz 2.4mg</name>
      <labeller>Ksl Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01996835</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-08</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lemon Menthol Antiseptic Throat Loz 2.4mg</name>
      <labeller>Ksl Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01996851</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Medi-First Plus Sore Throat Max</name>
      <labeller>Unifirst First Aid</labeller>
      <ndc-id/>
      <ndc-product-code>47682-909</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on>2014-01-08</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Medique Sepasoothe</name>
      <labeller>Unifirst First Aid</labeller>
      <ndc-id/>
      <ndc-product-code>47682-144</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-03-08</started-marketing-on>
      <ended-marketing-on>2014-06-13</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mint Antiseptic Throat Lozenges 2.4mg/loz</name>
      <labeller>Ksl Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01996843</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-09</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Myxcin-C</name>
      <labeller>Phoenix Global Supply Group, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52426-520</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1.1 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>part333A</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Otis Clapp Thorets</name>
      <labeller>Unifirst First Aid</labeller>
      <ndc-id/>
      <ndc-product-code>47682-573</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-12-30</started-marketing-on>
      <ended-marketing-on>2014-05-10</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>S.T.37</name>
      <labeller>Numark Brands, Inc</labeller>
      <ndc-id/>
      <ndc-product-code>69846-860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1929-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1.1 mg/1mL</strength>
      <route>Oral; Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Soothe Aid Loz 2.4mg</name>
      <labeller>Zee Medical</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00806668</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>2012-07-31</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Strepsils Anaesthetic Formula</name>
      <labeller>Rb Health (Canada) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02243888</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-10-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Strepsils Extra Black Cherry</name>
      <labeller>Rb Health (Canada) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02263998</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-03-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sucrets Cherry Vapour Action Loz</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01951726</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1998-08-25</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sucrets Extra Strength Cherry Lozenges</name>
      <labeller>Heritage Brands, A Subsidiary Of Insight Pharmaceuticals Llc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01951734</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-01-01</started-marketing-on>
      <ended-marketing-on>2016-04-30</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sucrets Extra Strength Mint Loz</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01951742</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-12</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sucrets Honey Lemon Vapour Action Loz</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01951769</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-12</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sucrets Original Mint</name>
      <labeller>Insight Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>63736-851</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-28</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength>2.4 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>part356</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sucrets Regular Mint Loz</name>
      <labeller>Smithkline Beecham Consumer Healthcare, Division Of Smithkline Beecham Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01951793</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-12</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Throat Loz 2.4mg Cherry</name>
      <labeller>Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01968785</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-09-17</ended-marketing-on>
      <dosage-form>Lozenge</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Green Guard Sore Throat Relief</name>
      <ingredients>Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Medique Sepasoothe</name>
      <ingredients>Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Otis Clapp Thorets</name>
      <ingredients>Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Medi-First Plus Sore Throat Max</name>
      <ingredients>Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Myxcin-C</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Avapta</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Avapta</name>
      <ingredients>Allantoin + Camphor + Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Avapta</name>
      <ingredients>Benzalkonium + Hexylresorcinol + Zinc chloride</ingredients>
    </mixture>
    <mixture>
      <name>Sucrets Original Mint</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>S.T.37</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Strepsils Anaesthetic Formula</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Strepsils Extra Black Cherry</name>
      <ingredients>Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Honey Eucalyptus Antiseptic Throat Loz 2.4mg</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Mint Antiseptic Throat Lozenges 2.4mg/loz</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Lemon Menthol Antiseptic Throat Loz 2.4mg</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Cherry Antiseptic Throat Lozenges 2.4mg/loz</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Throat Loz 2.4mg Cherry</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Soothe Aid Loz 2.4mg</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Antiseptic Sore Throat Loz(honey Eucalyp.fl)</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Antiseptic Sore Throat Loz. (lemon Flavour)</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Antiseptic Sore Throat Loz(mint Menthol Flv)</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Antiseptic Throat Lozenges (with Hexylresorcinol)</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bradosol Multiflavour Loz 2.4mg</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Sucrets Extra Strength Mint Loz</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Sucrets Cherry Vapour Action Loz</name>
      <ingredients>Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Sucrets Honey Lemon Vapour Action Loz</name>
      <ingredients>Hexylresorcinol + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Sucrets Regular Mint Loz</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bronchodex Pastilles Antiseptiques-S.cerise</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bronchodex Past.antisep.-s.miel Et Eucalypt.</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bronchodex Past.antisept. Extra Fortes-S.cer</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bronchodex Pastilles Antiseptiques-S.menthe</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Sucrets Extra Strength Cherry Lozenges</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bradosol Lozenges Extra Strength 3.5mg Mint</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bradosol Lozenges Extra Strength 3.5mg</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
    <mixture>
      <name>Bradosol Lozenges Regular Strength 2.4mg (cherry, Mint, Lemon, Orange, Honey-eucalyptus)</name>
      <ingredients>Hexylresorcinol</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anthelmintics</category>
      <mesh-id>D000871</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents, Local</category>
      <mesh-id>D000891</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Agents</category>
      <mesh-id>D000977</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Miscellaneous Anti-infectives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Phenols</category>
      <mesh-id>D010636</mesh-id>
    </category>
    <category>
      <category>Resorcinols</category>
      <mesh-id>D012118</mesh-id>
    </category>
    <category>
      <category>Throat Preparations</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Spray</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Oral</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Spray</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Lozenge</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>1.1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral; Topical</route>
      <strength>1.1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Lozenge</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Lozenge</form>
      <route>Oral</route>
      <strength>2.4 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="R02AA12">
      <level code="R02AA">Antiseptics</level>
      <level code="R02A">THROAT PREPARATIONS</level>
      <level code="R02">THROAT PREPARATIONS</level>
      <level code="R">RESPIRATORY SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:04.92</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.77</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-2.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.54e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-hexylbenzene-1,3-diol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>oxana</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>194.2701</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>194.13067982</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCCC1=C(O)C=C(O)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C12H18O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>WFJIVOKAWHGMBH-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>40.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>58.07</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>22.98</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-5.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>700</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>93749</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>3610</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827952</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>21106121</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50292636</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Hexylresorcinol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL443605</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000971</id>
      <name>DNA topoisomerase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L2736</ref-id>
            <title>Hexylresorcinol: Providing Skin Benefits by Modulating Multiple Molecular Targets</title>
            <url>https://www.researchgate.net/publication/283776287_Hexylresorcinol_Providing_Skin_Benefits_by_Modulating_Multiple_Molecular_Targets</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11387" source="Swiss-Prot">
        <name>DNA topoisomerase 1</name>
        <general-function>Poly(a) rna binding</general-function>
        <specific-function>Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex. Introduces a single-strand break via transesterification at a target site in duplex DNA. The scissile phosphodiester is attacked by the catalytic tyrosine of the enzyme, resulting in the formation of a DNA-(3'-phosphotyrosyl)-enzyme intermediate and the expulsion of a 5'-OH DNA strand. The free DNA strand then undergoes passage around the unbroken strand thus removing DNA supercoils. Finally, in the religation step, the DNA 5'-OH attacks the covalent intermediate to expel the active-site tyrosine and restore the DNA phosphodiester backbone (By similarity). Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Involved in the circadian transcription of the core circadian clock component ARNTL/BMAL1 by altering the chromatin structure around the ROR response elements (ROREs) on the ARNTL/BMAL1 promoter.</specific-function>
        <gene-name>TOP1</gene-name>
        <locus>20q12-q13.1</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.95</theoretical-pi>
        <molecular-weight>90725.19</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11986</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TOP1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03250</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>339806</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11387</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TOP1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5.99.1.2</synonym>
          <synonym>DNA topoisomerase I</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001933|DNA topoisomerase 1
MSGDHLHNDSQIEADFRLNDSHKHKDKHKDREHRHKEHKKEKDREKSKHSNSEHKDSEKK
HKEKEKTKHKDGSSEKHKDKHKDRDKEKRKEEKVRASGDAKIKKEKENGFSSPPQIKDEP
EDDGYFVPPKEDIKPLKRPRDEDDADYKPKKIKTEDTKKEKKRKLEEEEDGKLKKPKNKD
KDKKVPEPDNKKKKPKKEEEQKWKWWEEERYPEGIKWKFLEHKGPVFAPPYEPLPENVKF
YYDGKVMKLSPKAEEVATFFAKMLDHEYTTKEIFRKNFFKDWRKEMTNEEKNIITNLSKC
DFTQMSQYFKAQTEARKQMSKEEKLKIKEENEKLLKEYGFCIMDNHKERIANFKIEPPGL
FRGRGNHPKMGMLKRRIMPEDIIINCSKDAKVPSPPPGHKWKEVRHDNKVTWLVSWTENI
QGSIKYIMLNPSSRIKGEKDWQKYETARRLKKCVDKIRNQYREDWKSKEMKVRQRAVALY
FIDKLALRAGNEKEEGETADTVGCCSLRVEHINLHPELDGQEYVVEFDFLGKDSIRYYNK
VPVEKRVFKNLQLFMENKQPEDDLFDRLNTGILNKHLQDLMEGLTAKVFRTYNASITLQQ
QLKELTAPDENIPAKILSYNRANRAVAILCNHQRAPPKTFEKSMMNLQTKIDAKKEQLAD
ARRDLKSAKADAKVMKDAKTKKVVESKKKAVQRLEEQLMKLEVQATDREENKQIALGTSK
LNYLDPRITVAWCKKWGVPIEKIYNKTQREKFAWAIDMADEDYEF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016271|DNA topoisomerase 1 (TOP1)
ATGAGTGGGGACCACCTCCACAACGATTCCCAGATCGAAGCGGATTTCCGATTGAATGAT
TCTCATAAACACAAAGATAAACACAAAGATCGAGAACACCGGCACAAAGAACACAAGAAG
GAGAAGGACCGGGAAAAGTCCAAGCATAGCAACAGTGAACATAAAGATTCTGAAAAGAAA
CACAAAGAGAAGGAGAAGACCAAACACAAAGATGGAAGCTCAGAAAAGCATAAAGACAAA
CATAAAGACAGAGACAAGGAAAAACGAAAAGAGGAAAAGGTTCGAGCCTCTGGGGATGCA
AAAATAAAGAAGGAGAAGGAAAATGGCTTCTCTAGTCCACCACAAATTAAAGATGAACCT
GAAGATGATGGCTATTTTGTTCCTCCTAAAGAGGATATAAAGCCATTAAAGAGACCTCGA
GATGAGGATGATGCTGATTATAAACCTAAGAAAATTAAAACAGAAGATACCAAGAAGGAG
AAGAAAAGAAAACTAGAAGAAGAAGAGGATGGTAAATTGAAAAAACCCAAGAATAAAGAT
AAAGATAAAAAAGTTCCTGAGCCAGATAACAAGAAAAAGAAGCCGAAGAAAGAAGAGGAA
CAGAAGTGGAAATGGTGGGAAGAAGAGCGCTATCCTGAAGGCATCAAGTGGAAATTCCTA
GAACATAAAGGTCCAGTATTTGCCCCACCATATGAGCCTCTTCCAGAGAATGTCAAGTTT
TATTATGATGGTAAAGTCATGAAGCTGAGCCCCAAAGCAGAGGAAGTAGCTACGTTCTTT
GCAAAAATGCTCGACCATGAATATACTACCAAGGAAATATTTAGGAAAAATTTCTTTAAA
GACTGGAGAAAGGAAATGACTAATGAAGAGAAGAATATTATCACCAACCTAAGCAAATGT
GATTTTACCCAGATGAGCCAGTATTTCAAAGCCCAGACGGAAGCTCGGAAACAGATGAGC
AAGGAAGAGAAACTGAAAATCAAAGAGGAGAATGAAAAATTACTGAAAGAATATGGATTC
TGTATTATGGATAACCACAAAGAGAGGATTGCTAACTTCAAGATAGAGCCTCCTGGACTT
TTCCGTGGCCGCGGCAACCACCCCAAGATGGGCATGCTGAAGAGACGAATCATGCCCGAG
GATATAATCATCAACTGTAGCAAAGATGCCAAGGTTCCTTCTCCTCCTCCAGGACATAAG
TGGAAAGAAGTCCGGCATGATAACAAGGTTACTTGGCTGGTTTCCTGGACAGAGAACATC
CAAGGTTCCATTAAATACATCATGCTTAACCCTAGTTCACGAATCAAGGGTGAGAAGGAC
TGGCAGAAATACGAGACTGCTCGGCGGCTGAAAAAATGTGTGGACAAGATCCGGAACCAG
TATCGAGAAGACTGGAAGTCCAAAGAGATGAAAGTCCGGCAGAGAGCTGTAGCCCTGTAC
TTCATCGACAAGCTTGCTCTGAGAGCAGGCAATGAAAAGGAGGAAGGAGAAACAGCGGAC
ACTGTGGGCTGCTGCTCACTTCGTGTGGAGCACATCAATCTACACCCAGAGTTGGATGGT
CAGGAATATGTGGTAGAGTTTGACTTCCTCGGGAAGGACTCCATCAGATACTATAACAAG
GTCCCTGTTGAGAAACGAGTTTTTAAGAACCTACAACTATTTATGGAGAACAAGCAGCCC
GAGGATGATCTTTTTGATAGACTCAATACTGGTATTCTGAATAAGCATCTTCAGGATCTC
ATGGAGGGCTTGACAGCCAAGGTATTCCGTACATACAATGCCTCCATCACGCTACAGCAG
CAGCTAAAAGAACTGACAGCCCCGGATGAGAACATCCCAGCGAAGATCCTTTCTTATAAC
CGTGCCAATCGAGCTGTTGCAATTCTTTGTAACCATCAGAGGGCACCACCAAAAACTTTT
GAGAAGTCTATGATGAACTTGCAAACTAAGATTGATGCCAAGAAGGAACAGCTAGCAGAT
GCCCGGAGAGACCTGAAAAGTGCTAAGGCTGATGCCAAGGTCATGAAGGATGCAAAGACG
AAGAAGGTAGTAGAGTCAAAGAAGAAGGCTGTTCAGAGACTGGAGGAACAGTTGATGAAG
CTGGAAGTTCAAGCCACAGACCGAGAGGAAAATAAACAGATTGCCCTGGGAACCTCCAAA
CTCAATTATCTGGACCCTAGGATCACAGTGGCTTGGTGCAAGAAGTGGGGTGTCCCAATT
GAGAAGATTTACAACAAAACCCAGCGGGAGAAGTTTGCCTGGGCCATTGACATGGCTGAT
GAAGACTATGAGTTTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01028</identifier>
            <name>Topoisom_I</name>
          </pfam>
          <pfam>
            <identifier>PF02919</identifier>
            <name>Topoisom_I_N</name>
          </pfam>
          <pfam>
            <identifier>PF14370</identifier>
            <name>Topo_C_assoc</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic mRNA processing body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleolus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>replication fork protection complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>core promoter sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA topoisomerase type I activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA topoisomerase type II (ATP-hydrolyzing) activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>poly(A) RNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromosome segregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA topological change</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic cleavage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0001035</id>
      <name>Protein-glutamine gamma-glutamyltransferase 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L2736</ref-id>
            <title>Hexylresorcinol: Providing Skin Benefits by Modulating Multiple Molecular Targets</title>
            <url>https://www.researchgate.net/publication/283776287_Hexylresorcinol_Providing_Skin_Benefits_by_Modulating_Multiple_Molecular_Targets</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21980" source="Swiss-Prot">
        <name>Protein-glutamine gamma-glutamyltransferase 2</name>
        <general-function>Protein-glutamine gamma-glutamyltransferase activity</general-function>
        <specific-function>Catalyzes the cross-linking of proteins and the conjugation of polyamines to proteins.</specific-function>
        <gene-name>TGM2</gene-name>
        <locus>20q12</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.86</theoretical-pi>
        <molecular-weight>77328.21</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TGM2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M55153</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>339521</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21980</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TGM2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.3.2.13</synonym>
          <synonym>TG(C)</synonym>
          <synonym>TGase C</synonym>
          <synonym>TGase H</synonym>
          <synonym>TGase-2</synonym>
          <synonym>TGC</synonym>
          <synonym>Tissue transglutaminase</synonym>
          <synonym>Transglutaminase C</synonym>
          <synonym>Transglutaminase H</synonym>
          <synonym>Transglutaminase-2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002061|Protein-glutamine gamma-glutamyltransferase 2
MAEELVLERCDLELETNGRDHHTADLCREKLVVRRGQPFWLTLHFEGRNYEASVDSLTFS
VVTGPAPSQEAGTKARFPLRDAVEEGDWTATVVDQQDCTLSLQLTTPANAPIGLYRLSLE
ASTGYQGSSFVLGHFILLFNAWCPADAVYLDSEEERQEYVLTQQGFIYQGSAKFIKNIPW
NFGQFEDGILDICLILLDVNPKFLKNAGRDCSRRSSPVYVGRVVSGMVNCNDDQGVLLGR
WDNNYGDGVSPMSWIGSVDILRRWKNHGCQRVKYGQCWVFAAVACTVLRCLGIPTRVVTN
YNSAHDQNSNLLIEYFRNEFGEIQGDKSEMIWNFHCWVESWMTRPDLQPGYEGWQALDPT
PQEKSEGTYCCGPVPVRAIKEGDLSTKYDAPFVFAEVNADVVDWIQQDDGSVHKSINRSL
IVGLKISTKSVGRDEREDITHTYKYPEGSSEEREAFTRANHLNKLAEKEETGMAMRIRVG
QSMNMGSDFDVFAHITNNTAEEYVCRLLLCARTVSYNGILGPECGTKYLLNLNLEPFSEK
SVPLCILYEKYRDCLTESNLIKVRALLVEPVINSYLLAERDLYLENPEIKIRILGEPKQK
RKLVAEVSLQNPLPVALEGCTFTVEGAGLTEEQKTVEIPDPVEAGEEVKVRMDLLPLHMG
LHKLVVNFESDKLKAVKGFRNVIIGPA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010725|Protein-glutamine gamma-glutamyltransferase 2 (TGM2)
ATGGCCGAGGAGCTGGTCTTAGAGAGGTGTGATCTGGAGCTGGAGACCAATGGCCGAGAC
CACCACACGGCCGACCTGTGCCGGGAGAAGCTGGTGGTGCGACGGGGCCAGCCCTTCTGG
CTGACCCTGCACTTTGAGGGCCGCAACTACGAGGCCAGTGTAGACAGTCTCACCTTCAGT
GTCGTGACCGGCCCAGCCCCTAGCCAGGAGGCCGGGACCAAGGCCCGTTTTCCACTAAGA
GATGCTGTGGAGGAGGGTGACTGGACAGCCACCGTGGTGGACCAGCAAGACTGCACCCTC
TCGCTGCAGCTCACCACCCCGGCCAACGCCCCCATCGGCCTGTATCGCCTCAGCCTGGAG
GCCTCCACTGGCTACCAGGGATCCAGCTTTGTGCTGGGCCACTTCATTTTGCTCTTCAAC
GCCTGGTGCCCAGCGGATGCTGTGTACCTGGACTCGGAAGAGGAGCGGCAGGAGTATGTC
CTCACCCAGCAGGGCTTTATCTACCAGGGCTCGGCCAAGTTCATCAAGAACATACCTTGG
AATTTTGGGCAGTTTGAAGATGGGATCCTAGACATCTGCCTGATCCTTCTAGATGTCAAC
CCCAAGTTCCTGAAGAACGCCGGCCGTGACTGCTCCCGCCGCAGCAGCCCCGTCTACGTG
GGCCGGGTGGTGAGTGGCATGGTCAACTGCAACGATGACCAGGGTGTGCTGCTGGGACGC
TGGGACAACAACTACGGGGACGGCGTCAGCCCCATGTCCTGGATCGGCAGCGTGGACATC
CTGCGGCGCTGGAAGAACCACGGCTGCCAGCGCGTCAAGTATGGCCAGTGCTGGGTCTTC
GCCGCCGTGGCCTGCACAGTGCTGAGGTGCCTGGGCATCCCTACCCGCGTCGTGACCAAC
TACAACTCGGCCCATGACCAGAACAGCAACCTTCTCATCGAGTACTTCCGCAATGAGTTT
GGGGAGATCCAGGGTGACAAGAGCGAGATGATCTGGAACTTCCACTGCTGGGTGGAGTCG
TGGATGACCAGGCCGGACCTGCAGCCGGGGTACGAGGGCTGGCAGGCCCTGGACCCAACG
CCCCAGGAGAAGAGCGAAGGGACGTACTGCTGTGGCCCAGTTCCAGTTCGTGCCATCAAG
GAGGGCGACCTGAGCACCAAGTACGATGCGCCCTTTGTCTTTGCGGAGGTCAATGCCGAC
GTGGTAGACTGGATCCAGCAGGACGATGGGTCTGTGCACAAATCCATCAACCGTTCCCTG
ATCGTTGGGCTGAAGATCAGCACTAAGAGCGTGGGCCGAGACGAGCGGGAGGATATCACC
CACACCTACAAATACCCAGAGGGGTCCTCAGAGGAGAGGGAGGCCTTCACAAGGGCGAAC
CACCTGAACAAACTGGCCGAGAAGGAGGAGACAGGGATGGCCATGCGGATCCGTGTGGGC
CAGAGCATGAACATGGGCAGTGACTTTGACGTCTTTGCCCACATCACCAACAACACCGCT
GAGGAGTACGTCTGCCGCCTCCTGCTCTGTGCCCGCACCGTCAGCTACAATGGGATCTTG
GGGCCCGAGTGTGGCACCAAGTACCTGCTCAACCTCAACCTGGAGCCTTTCTCTGAGAAG
AGCGTTCCTCTTTGCATCCTCTATGAGAAATACCGTGACTGCCTTACGGAGTCCAACCTC
ATCAAGGTGCGGGCCCTCCTCGTGGAGCCAGTTATCAACAGCTACCTGCTGGCTGAGAGG
GACCTCTACCTGGAGAATCCAGAAATCAAGATCCGGATCCTTGGGGAGCCCAAGCAGAAA
CGCAAGCTGGTGGCTGAGGTGTCCCTGCAGAACCCGCTCCCTGTGGCCCTGGAAGGCTGC
ACCTTCACTGTGGAGGGGGCCGGCCTGACTGAGGAGCAGAAGACGGTGGAGATCCCAGAC
CCCGTGGAGGCAGGGGAGGAAGTTAAGGTGAGAATGGACCTGCTGCCGCTCCACATGGGC
CTCCACAAGCTGGTGGTGAACTTCGAGAGCGACAAGCTGAAGGCTGTGAAGGGCTTCCGG
AATGTCATCATTGGCCCCGCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01841</identifier>
            <name>Transglut_core</name>
          </pfam>
          <pfam>
            <identifier>PF00868</identifier>
            <name>Transglut_N</name>
          </pfam>
          <pfam>
            <identifier>PF00927</identifier>
            <name>Transglut_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>focal adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein-glutamine gamma-glutamyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic cell clearance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>branching involved in salivary gland morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of endoplasmic reticulum calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptide cross-linking</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitochondrial calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>salivary gland cavitation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000252</id>
      <name>Tyrosinase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L2736</ref-id>
            <title>Hexylresorcinol: Providing Skin Benefits by Modulating Multiple Molecular Targets</title>
            <url>https://www.researchgate.net/publication/283776287_Hexylresorcinol_Providing_Skin_Benefits_by_Modulating_Multiple_Molecular_Targets</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P14679" source="Swiss-Prot">
        <name>Tyrosinase</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the rate-limiting conversions of tyrosine to DOPA, DOPA to DOPA-quinone and possibly 5,6-dihydroxyindole to indole-5,6 quinone.</specific-function>
        <gene-name>TYR</gene-name>
        <locus>11q14-q21</locus>
        <cellular-location>Melanosome membrane</cellular-location>
        <transmembrane-regions>477-497</transmembrane-regions>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.05</theoretical-pi>
        <molecular-weight>60392.69</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12442</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TYR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M27160</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>340037</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14679</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TYRO_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.18.1</synonym>
          <synonym>LB24-AB</synonym>
          <synonym>Monophenol monooxygenase</synonym>
          <synonym>SK29-AB</synonym>
          <synonym>Tumor rejection antigen AB</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000503|Tyrosinase
MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILL
SNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVR
RNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMH
YYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRD
AEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRN
PGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASPLTGIADASQS
SMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGH
NRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLG
AAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021257|Tyrosinase (TYR)
ATGCTCCTGGCTGTTTTGTACTGCCTGCTGTGGAGTTTCCAGACCTCCGCTGGCCATTTC
CCTAGAGCCTGTGTCTCCTCTAAGAACCTGATGGAGAAGGAATGCTGTCCACCGTGGAGC
GGGGACAGGAGTCCCTGTGGCCAGCTTTCAGGCAGAGGTTCCTGTCAGAATATCCTTCTG
TCCAATGCACCACTTGGGCCTCAATTTCCCTTCACAGGGGTGGATGACCGGGAGTCGTGG
CCTTCCGTCTTTTATAATAGGACCTGCCAGTGCTCTGGCAACTTCATGGGATTCAACTGT
GGAAACTGCAAGTTTGGCTTTTGGGGACCAAACTGCACAGAGAGACGACTCTTGGTGAGA
AGAAACATCTTCGATTTGAGTGCCCCAGAGAAGGACAAATTTTTTGCCTACCTCACTTTA
GCAAAGCATACCATCAGCTCAGACTATGTCATCCCCATAGGGACCTATGGCCAAATGAAA
AATGGATCAACACCCATGTTTAACGACATCAATATTTATGACCTCTTTGTCTGGATGCAT
TATTATGTGTCAATGGATGCACTGCTTGGGGGATCTGAAATCTGGAGAGACATTGATTTT
GCCCATGAAGCACCAGCTTTTCTGCCTTGGCATAGACTCTTCTTGTTGCGGTGGGAACAA
GAAATCCAGAAGCTGACAGGAGATGAAAACTTCACTATTCCATATTGGGACTGGCGGGAT
GCAGAAAAGTGTGACATTTGCACAGATGAGTACATGGGAGGTCAGCACCCCACAAATCCT
AACTTACTCAGCCCAGCATCATTCTTCTCCTCTTGGCAGATTGTCTGTAGCCGATTGGAG
GAGTACAACAGCCATCAGTCTTTATGCAATGGAACGCCCGAGGGACCTTTACGGCGTAAT
CCTGGAAACCATGACAAATCCAGAACCCCAAGGCTCCCCTCTTCAGCTGATGTAGAATTT
TGCCTGAGTTTGACCCAATATGAATCTGGTTCCATGGATAAAGCTGCCAATTTCAGCTTT
AGAAATACACTGGAAGGATTTGCTAGTCCACTTACTGGGATAGCGGATGCCTCTCAAAGC
AGCATGCACAATGCCTTGCACATCTATATGAATGGAACAATGTCCCAGGTACAGGGATCT
GCCAACGATCCTATCTTCCTTCTTCACCATGCATTTGTTGACAGTATTTTTGAGCAGTGG
CTCCGAAGGCACCGTCCTCTTCAAGAAGTTTATCCAGAAGCCAATGCACCCATTGGACAT
AACCGGGAATCCTACATGGTTCCTTTTATACCACTGTACAGAAATGGTGATTTCTTTATT
TCATCCAAAGATCTGGGCTATGACTATAGCTATCTACAAGATTCAGACCCAGACTCTTTT
CAAGACTACATTAAGTCCTATTTGGAACAAGCGAGTCGGATCTGGTCATGGCTCCTTGGG
GCGGCGATGGTAGGGGCCGTCCTCACTGCCCTGCTGGCAGGGCTTGTGAGCTTGCTGTGT
CGTCACAAGAGAAAGCAGCTTCCTGAAGAAAAGCAGCCACTCCTCATGGAGAAAGAGGAT
TACCACAGCTTGTATCAGAGCCATTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00264</identifier>
            <name>Tyrosinase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi-associated vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>melanosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>melanosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monophenol monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular nitrogen compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eye pigment biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>melanin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>melanin biosynthetic process from tyrosine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cAMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to UV</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin D</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thymus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>